By serving as the cofactor for the enzyme, activated factor Vll (FVIIa), tissue factor (TF) is critical for hemostasis. Preclinical and clinical data, however, have implicated TF in the progression and/or complications associated with a multitude of pathological conditions including atherothrombosis, ischemia/reperfusion injury, sepsis, acute lung injury/acute respiratory distress syndrome (ALI/ARDS), thrombotic microangiopathy (e.g. hemolytic uremic syndrome associated with E. coli verotoxin, certain drugs, and ricin toxicity), glomerulonephritis, antiphospholipid syndrome, inflammatory bowel disease, hepafic veno-occlusive disease (aka sinusoidal obstruction syndrome, associated with chemotherapy and following bone marrow transplantation), arthritis, organ transplant rejection, sickle cell anemia, cancer growth and metastasis, chemotherapy-associated thrombosis (e.g. thalidomide, lenalidomide) and post-surgical venous thromboembolic disease. Therefore the development of an agent(s) that could safely limit the action of TF would conceivably improve the medical therapy for many people.
Showing the most recent 10 out of 87 publications
